MM120 (LSD D-Tartrate)
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Generalized Anxiety Disorder
Conditions
Generalized Anxiety Disorder
Trial Timeline
Jan 29, 2025 → May 1, 2027
NCT ID
NCT06809595About MM120 (LSD D-Tartrate)
MM120 (LSD D-Tartrate) is a phase 3 stage product being developed by Definium Therapeutics for Generalized Anxiety Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06809595. Target conditions include Generalized Anxiety Disorder.
What happened to similar drugs?
6 of 20 similar drugs in Generalized Anxiety Disorder were approved
Approved (6) Terminated (3) Active (12)
Hype Score Breakdown
Clinical
17
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06941844 | Phase 3 | Active |
| NCT06809595 | Phase 3 | Recruiting |
| NCT06741228 | Phase 3 | Recruiting |
Competing Products
20 competing products in Generalized Anxiety Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + placebo | Eli Lilly | Phase 2/3 | 38 |
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 32 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Perampanel + Placebo comparator | Eisai | Phase 3 | 40 |
| zonisamide | Eisai | Pre-clinical | 26 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Fycompa | Eisai | Pre-clinical | 26 |
| Perampanel | Eisai | Phase 3 | 40 |
| Perampanel | Eisai | Pre-clinical | 26 |
| Cenobamate | Ono Pharmaceutical | Phase 3 | 47 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 40 |
| Duloxetine + Placebo | Eli Lilly | Approved | 43 |
| Ixekizumab | Eli Lilly | Approved | 43 |
| eszopiclone + eszopiclone + Placebo | Sumitomo Pharma | Phase 2 | 35 |
| Usual dose treatment of Tandospirone + Comparative high dose of tandospirone treatment | Sumitomo Pharma | Approved | 43 |
| ABBV-932 + Placebo for ABBV-932 + Antidepressant Therapy (ADT) | AbbVie | Phase 2 | 42 |
| Cariprazine 0.75 mg/day + Cariprazine 1.5 mg/day + Cariprazine 3.0 mg/day | AbbVie | Phase 2 | 27 |
| ABBV-932 + Placebo | AbbVie | Phase 1 | 29 |
| Escitalopram | AbbVie | Approved | 43 |
| Adalimumab | AbbVie | Phase 3 | 40 |